KYMERA THERAPEUTICS, INC. Prepaid Expense and Other Assets, Current
KYMERA THERAPEUTICS, INC. (KYMR) had Prepaid Expense and Other Assets, Current of $26.28 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-05
- 2026-06-30: Prepaid Expense and Other Assets, Current $26.28M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $26.50M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $22.94M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $22.62M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $26.28M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $26.50M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $22.94M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $22.62M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $22.88M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $17.80M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $21.52M 10-K · filed 2026-02-26 | $20.58M 10-K · filed 2025-02-27 |
| 2024-09-30 | $17.43M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $13.75M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $14.68M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $11.67M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $14.09M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $13.71M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $11.35M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $9.71M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $9.23M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $8.09M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $9.31M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $8.72M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $5.77M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $4.79M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $5.52M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $4.70M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $2.95M 10-Q · filed 2020-11-05 | |
| 2019-12-31 | $888.00K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |